[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Yongjun Wang\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":78},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100650474","phase-3-tenecteplase-or-reteplase-as-bridging-thrombolysis-before-thrombectomy-in-acute-ischemic-cerebrovascular-events-100650474",false,"NCT07748039","Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular Events","Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular Events (TRACE-BRIDGE): A Multicenter, Randomized, Open-Label, Three-Arm, Blinded-Endpoint Phase III Trial","TRACE- BRIDGE","Inclusion Criteria:\n\n1. Patients with acute ischemic stroke presenting within 4.5 hours of symptom onset who are eligible for intravenous thrombolytic therapy. A baseline non-contrast CT or MRI is required for screening.\n2. Large vessel occlusion on computed tomographic angiography (CTA) or magnetic resonance angiography (MRA) of the intracranial carotid artery (ICA) or middle cerebral artery (MCA) M1\n3. Age ⩾ 18 years at the time of signing the informed consent form\n4. ASPECTS 6-10\n5. Informed consent from the patients or their legal representative.\n\nExclusion Criteria:\n\n1. Intracranial hemorrhage (ICH) identified by CT or MRI\n2. Rapidly improving symptoms at the discretion of the investigator\n3. mRS \\> 2 before stroke onset.\n4. Massive cerebral infarction (infarct size greater than one-third of the blood middle cerebral artery supply area) suggested by CT.\n5. Known contraindication to imaging with contrast agents\n6. Planned adjunct intra-arterial (IA) thrombolysis during or after endovascular treatment (EVT).\n7. Secondary transfer from a primary stroke center\n8. Any terminal illness such that patient would not be expected to survive more than one year\n9. Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study\n10. Pregnant women","ALL","18 Years",{"count":20,"type":21},1440,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Acute ischemic stroke caused by large vessel occlusion (LVO) is a major cause of disability, and mechanical thrombectomy (MT) has become the standard treatment for eligible patients. However, the optimal role of intravenous thrombolysis before MT remains uncertain.\n\nThe TRACE-BRIDGE trial is a phase 3, investigator-initiated, multicenter, randomized, open-label trial with blinded outcome assessment (PROBE design) evaluating different bridging thrombolysis strategies before MT. The trial will enroll adults with acute ischemic stroke presenting within 4.5 hours of symptom onset and with imaging-confirmed anterior circulation LVO who are eligible for intravenous thrombolysis and MT.\n\nParticipants will be randomly assigned in a 1:1:1 ratio to receive tenecteplase plus MT, reteplase plus MT, or direct MT alone. The TRACE-BRIDGE trial aims to evaluate the efficacy and safety of bridging thrombolysis with tenecteplase or reteplase before mechanical thrombectomy compared with direct mechanical thrombectomy. The primary outcome is functional independence, defined as a modified Rankin Scale score of 0-2 at 90 days after randomization. If superiority of bridging thrombolysis is demonstrated, the trial will further evaluate whether reteplase is non-inferior to tenecteplase as a bridging thrombolytic strategy.",[27,28,29],"Acute Ischemic Stroke","Large Vessel Occlusion","Anterior Circulation Brain Infarction",[31,32,33,34,35],"acute ischemic stroke","thrombolysis","thrombectomy","tenecteplase","reteplase","NOT_YET_RECRUITING","2026-08-03",{"date":39,"type":40},"2026-08-05","ACTUAL",{"date":42,"type":21},"2026-08-01",{"date":44,"type":21},"2029-08-01",{"name":46,"class":47},"Yongjun Wang","OTHER",5,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100553913","phase-2-emergency-stroke-unit-for-acute-cerebrovascular-events--esu-ace-b--100553913","NCT06492265","Emergency Stroke Unit for Acute Cerebrovascular Events ( ESU-ACE-B )","Emergency Stroke Unit for Acute Cerebrovascular Events--A Prospective, Multicenter, Week-wise Randomized, Controlled Trial ( ESU-ACE-B )","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Can be treated between 4.5-6 hours of symptoms onset\\*(\\*Symptom onset is defined by the \"last seen normal\" principle);\n3. Presenting with ischemic stroke symptoms;\n4. Pre-stroke mRS score 0-1;\n5. Baseline NIHSS score ≥ 5;\n6. Eligible for endovascular thrombectomy;\n7. Informed consent signed.\n\nExclusion Criteria:\n\n1. Baseline NIHSS score \\\u003C 5;\n2. Unable to undergo MRI because of claustrophobia;\n3. Patients with cardiac pacemaker\u002Fbrain pacemaker\u002Finsulin pump implantation;\n4. Definite contraindication for endovascular thrombectomy;\n5. Patients with postictal hemiparesis (Todd's paralysis) or those with concomitant neurological\u002Fpsychiatric conditions who are unable or unwilling to cooperate;\n6. Pregnant women, nursing mothers, or reluctance to use effective contraceptive measures during the period of trial;\n7. Participation in other interventional randomized clinical trials within 3 months before enrollment;\n8. Patients deemed unsuitable for participation in this trial by the investigator or those for whom participation in this trial may result in greater risks.",{"count":57,"type":21},100,[59],"PHASE2","To compare the door-to-puncture time of patients with hyperacute ischemic stroke (between 4.5-6 hours after the onset of symptoms) treated in a standard stroke unit adherent to guidelines versus treated in Emergency Stroke Unit (a new stroke unit based on low-field magnetic resonance imaging).",[62],"Ischemic Stroke, Acute",[64,65,66,67],"Emergency stroke unit","Low-field magnetic resonance imaging","Reperfusion therapy","Endovascular therapy","RECRUITING","2024-08-09",{"date":71,"type":40},"2024-08-12",{"date":73,"type":40},"2024-08-04",{"date":75,"type":21},"2025-04-01",{"name":46,"class":47},1,""]